Literature DB >> 31292115

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.

Anja Mottok1,2,3, Stacy S Hung1, Elizabeth A Chavez1, Bruce Woolcock1, Adèle Telenius1, Lauren C Chong1, Barbara Meissner1, Hisae Nakamura1, Christopher Rushton4, Elena Viganò1, Clementine Sarkozy1, Randy D Gascoyne1,2, Joseph M Connors1, Susana Ben-Neriah1, Andrew Mungall5, Marco A Marra5, Reiner Siebert3, David W Scott1, Kerry J Savage1, Christian Steidl1,2.   

Abstract

Primary mediastinal large B-cell lymphoma (PMBL) represents a clinically and pathologically distinct subtype of large B-cell lymphomas. Furthermore, molecular studies, including global gene expression profiling, have provided evidence that PMBL is more closely related to classical Hodgkin lymphoma (cHL). Although targeted sequencing studies have revealed a number of mutations involved in PMBL pathogenesis, a comprehensive description of disease-associated genetic alterations and perturbed pathways is still lacking. Here, we performed whole-exome sequencing of 95 PMBL tumors to inform on oncogenic driver genes and recurrent copy number alterations. The integration of somatic gene mutations with gene expression signatures provides further insights into genotype-phenotype interrelation in PMBL. We identified highly recurrent oncogenic mutations in the Janus kinase-signal transducer and activator of transcription and nuclear factor κB pathways, and provide additional evidence of the importance of immune evasion in PMBL (CIITA, CD58, B2M, CD274, and PDCD1LG2). Our analyses highlight the interferon response factor (IRF) pathway as a putative novel hallmark with frequent alterations in multiple pathway members (IRF2BP2, IRF4, and IRF8). In addition, our integrative analysis illustrates the importance of JAK1, RELB, and EP300 mutations driving oncogenic signaling. The identified driver genes were significantly more frequently mutated in PMBL compared with diffuse large B-cell lymphoma, whereas only a limited number of genes were significantly different between PMBL and cHL, emphasizing the close relation between these entities. Our study, performed on a large cohort of PMBL, highlights the importance of distinctive genetic alterations for disease taxonomy with relevance for diagnostic evaluation and therapeutic decision-making.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2019        PMID: 31292115     DOI: 10.1182/blood.2019001126

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Kirsty Wienand; Atanas Kamburov; Gabriel K Griffin; Pei-Hsuan Chen; Ana Lako; Robert A Redd; Claire M Cote; Matthew D Ducar; Aaron R Thorner; Scott J Rodig; Gad Getz; Margaret A Shipp
Journal:  Blood       Date:  2019-12-26       Impact factor: 22.113

2.  Gene expression profiling of gray zone lymphoma.

Authors:  Clémentine Sarkozy; Lauren Chong; Katsuyoshi Takata; Elizabeth A Chavez; Tomoko Miyata-Takata; Gerben Duns; Adèle Telenius; Merrill Boyle; Graham W Slack; Camille Laurent; Pedro Farinha; Thierry J Molina; Christiane Copie-Bergman; Diane Damotte; Gilles A Salles; Anja Mottok; Kerry J Savage; David W Scott; Alexandra Traverse-Glehen; Christian Steidl
Journal:  Blood Adv       Date:  2020-06-09

3.  Savior Siblings Might Rescue Fetal Lethality But Not Adult Lymphoma in Irf2bp2-Null Mice.

Authors:  Ragnar O Vilmundarson; Niloufar Heydarikhorneh; An Duong; Tiffany Ho; Kianoosh Keyhanian; Fariborz Soheili; Hsiao-Huei Chen; Alexandre F R Stewart
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 4.  Evolution in the definition and diagnosis of the Hodgkin lymphomas and related entities.

Authors:  Thomas A Tousseyn; Rebecca L King; Falko Fend; Andrew L Feldman; Pierre Brousset; Elaine S Jaffe
Journal:  Virchows Arch       Date:  2022-10-24       Impact factor: 4.535

5.  Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.

Authors:  Rosalie Griffin Waller; Robert J Klein; Joseph Vijai; James D McKay; Alyssa Clay-Gilmour; Xiaomu Wei; Michael J Madsen; Douglas W Sborov; Karen Curtin; Susan L Slager; Kenneth Offit; Celine M Vachon; Steven M Lipkin; Charles Dumontet; Nicola J Camp
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

6.  Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.

Authors:  Adam R Davis; Sara L Stone; Amanda R Oran; Robyn T Sussman; Siddharth Bhattacharyya; Jennifer J D Morrissette; Adam Bagg
Journal:  Mod Pathol       Date:  2020-12-12       Impact factor: 7.842

7.  Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.

Authors:  Jennifer L Crombie; Loretta J Nastoupil; Robert Redd; Kevin Tang; Geoffrey Shouse; Alex F Herrera; Victor A Chow; Mazyar Shadman; Omar Castaneda Puglianini; Anna Saucier; Caron A Jacobson; Philippe Armand; Gary Simmons
Journal:  Blood Adv       Date:  2021-09-28

Review 8.  Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.

Authors:  Mark Roschewski; James D Phelan; Wyndham H Wilson
Journal:  Cancer J       Date:  2020 May/Jun       Impact factor: 2.074

9.  Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.

Authors:  Bryan Rea; Yen-Chun Liu; Alanna Maguire; Lorinda A Soma; Chris M Bacon; Michael G Bayerl; Molly H Smith; Michael T Barrett; Steven H Swerdlow; Sarah E Gibson
Journal:  Mod Pathol       Date:  2021-12-24       Impact factor: 8.209

10.  Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.

Authors:  Stuart E Lacy; Sharon L Barrans; Philip A Beer; Daniel Painter; Alexandra G Smith; Eve Roman; Susanna L Cooke; Camilo Ruiz; Paul Glover; Suzan J L Van Hoppe; Nichola Webster; Peter J Campbell; Reuben M Tooze; Russell Patmore; Cathy Burton; Simon Crouch; Daniel J Hodson
Journal:  Blood       Date:  2020-05-14       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.